齐拉西酮长期应用于老年精神分裂症患者对其血栓病变发病率的影响分析  

作　　者：李雪丽 

机构地区：[1]广东省精神卫生研究所

出　　处：《当代医学》2011年第17期1-2,共2页Contemporary Medicine

摘　　要：目的探讨齐拉西酮长期应用于老年精神分裂症患者对其血栓病变发病率的影响。方法将102例精神分裂症患者作为研究对象,随机分为试验组和对照组,对照组给予阿立哌唑治疗,试验组给予齐拉西酮治疗。结果 (1)治疗后试验组和对照组PANSS得分均有显著性降低(P<0.05),但组间比较无显著性差异(P>0.05)。(2)两组不良反应发生率无显著性差异(P>0.05),试验组失眠症状较为明显,而对照组嗜睡和体重增加较为明显。(3)试验组血栓事件显著少于对照组(P<0.05)。结论对于肥胖以及有心脑血管疾病的老年患者,可以考虑使用齐拉西酮,以提高临床安全性。Objective To explore the clinical influence of ziprasidone used for therapy of older patients with schizophrenia long term on rate of thrombus disease.Methods 102 cases of older patients with schizophrenia as studied object were randomly divided into experimental group and control group,control group was given therapy of aripiprazole,experimental group was given therapy of ziprasidone.Results（1） After therapy,the PANSS scores in experimental group and in control group had significant decrease（P0.05）,but comparation between two groups had no significant difference（P0.05）.（2） The side-actions in two groups had no significant difference（P0.05）,insomnia in experimental group was palpable,and fat and drowsiness in control group was palpable.（3） The rate of CCVD complications in experimental group was significantly less than control group（P0.05）.Conclusion For the aim of enhancing clinical safety,fat and CCVD patients can choose ziprasidone for therapy.

关 键 词：齐拉西酮 精神分裂症 老年患者 血栓病变 

分 类 号：R749.3[医药卫生—神经病学与精神病学]